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Abstract: An uncomplicated, high-yielding synthetic route has been developed to constitute
complicated heterocycles, applying domino, click and retro-Diels–Alder (RDA) reaction sequences.
Starting from 2-aminocarboxamides, a new set of isoindolo[2,1-a]quinazolinones was synthesized
with domino ring closure. A click reaction was performed to create the 1,2,3-triazole heterocyclic ring,
followed by an RDA reaction resulting in dihydropyrimido[2,1-a]isoindole-2,6-diones. The absolute
configuration, concluded by the norbornene structure that served as a chiral source, remained
constant throughout the transformations. The structure of the synthesized compounds was examined
by 1H and 13C Nuclear Magnetic Resonance (NMR) methods.
Keywords: domino ring closure; click reaction; RDA reaction; stereoselectivity; regioselectivity;
traceless chirality transfer
1. Introduction
Compounds containing quinazoline and triazole heterocyclic rings play a significant role in
both organic and pharmaceutical chemistries. Quinazoline heterocycles are important subunits of
a broad diversity of synthetic pharmaceuticals as well as natural compounds with antiviral [1,2],
anti-inflammatory [3], antimalarial [4], and anticancer [5] activities. The synthesis of bioactive
saturated quinazoline derivatives was also investigated [6–8]. In the past few years, researchers
have exploited heterocycles containing the 1,2,3-triazole ring to generate many medicinal scaffolds
exhibiting anti-HIV [9], antibacterial [10–12] and anticancer activities [13,14]. Building a triazole ring
into a compound can change or even improve the pharmacokinetic properties of a drug [15–23].
There exist numerous methods, which are effective without using the classic and time-consuming
protection–deprotection processes as well as purification methodology of intermediates [24–27] in the
synthesis of diverse and complex chiral compounds from simple substrates in an economically suitable
manner. At the same time, the use of multi-component domino reactions in asymmetric synthesis
has gained a continuously increasing interest [28–32]. Asymmetric domino reactions are based on the
application of removable chiral auxiliaries and chiral reagents [24].
The 1,4-disubstituted 1,2,3-triazole function still plays an important role in drug discovery, which
justifies the continuous advancement of new strategies for their synthesis [33–35]. One of the most
widely used click-chemistry methods in this field is the copper-catalyzed 1,3-dipolar cycloaddition
between an alkyne and an azide (CuAAC), due to its simplicity and high selectivity [36–39].
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For synthetic chemists, the RDA reaction has become a valuable tool for their research towards the
design and synthesis of novel heterocyclic scaffolds, because of its efficiency in introducing a double
bond into a heterocyclic skeleton [40] along with enantiocontrolled [41] and enantiodivergent [42]
syntheses of heterocyclic compounds.
The skeletal transformations of heterocycles take its place in the construction of complex
molecular frameworks from simple feedstock among the most powerful synthetic strategies [43–45].
Within this context, domino ring closure and RDA are the predominant approaches, since they
lead to valuable nitrogenated heterocycles of high biological activity [46–53], such as isoindolo- and
pyrroloquinazolinones. In our laboratory, their reactivity and skeletal deformation have been widely
examined under mild conditions.
Continuing our work on the synthesis of novel N-heterocycles and focusing on the biological
potential of fused quinazolinones [47–53], herein we report the synthesis of a new series of isoindolo[2,1-a]
quinazolinones and pyrimido[2,1-a]isoindoles starting from 2-aminocarboxamides.
Our present aim was (i) to examine the diastereoselectivity of the domino ring-closure reaction
of N-propargyl-substituted diendo- and diexo-2-aminonorbornenecarboxamides with 2-formylbenzoic
acid, (ii) to develop Cu(I)-catalyzed azide/alkyne cycloaddition (CuAAC) in a regioselective manner,
(iii) to investigate the RDA reaction of the created isoindolo[2,1-a]quinazolinones, and (iv) to extend
this methodology to obtain different racemic and enantiomeric pyrimido[2,1-a]isoindole derivatives
containing a triazole ring.
2. Results
First, all methods were performed and optimized with racemic starting materials followed
by repeating the syntheses with the enantiomers. In Schemes 1 and 2 only a single enantiomer is
represented for evidence. Please note that all spectroscopic data of the racemic compounds were
identical to those of the enantiomeric samples.Molecules 2019, 24, x FOR PEER REVIEW  3 of 11 
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min; 71%; (vi) 1. 2-methylbenzyl chloride, NaN3, Et3N, H2O/tBuOH, r.t., 1 h, 2. sodium ascorbate, (−)-
6 or (−)-8, CuSO4, r.t. 8 h, 70–72%; (vii) MW, DCB, 220 °C, 60 min, 300 W, 70–72%. 
The reaction of propargylamides 5 and 14 with 2-formylbenzoic acid is plausibly interpreted as 
a domino process, in which the first step is the Schiff base formation [47,50]. The Schiff base 
undergoes ring closure to give isoindolo[2,1-a]quinazolinones 6 and 15, respectively. 
The reaction was implemented by dissolving (+)-5 and (+)-14 in ethanol using one equivalent of 
2-formylbenzoic acid and stirring the solution at 100 °C for 30 min under microwave irradiation in 
the presence of p-toluenesulfonic acid. The 1H NMR spectra revealed the formation of the 
isoindolo[2,1-a]quinazoline (−)-6 and (−)-15 (Schemes 1 and 2). 
 
Scheme 2. Reagents and conditions, see in Scheme 1, yields: (i) 85%; (ii) 85%; (iii) 72%; (iv-v) 70% (vi) 
70–72%; (vii) 70–72%. 
Scheme 1. Reagents and conditions: (i) H2O, MW 100 ◦C, 30 min, 300 W, 90%; (ii) Boc2O, NaOH,
dioxane/H2O, 0 ◦C, 30 min, r.t., 4 h, 87%; (iii) DIC, HOBt, propargylamine, THF, r.t., 24 h, 75%; (iv) 1.
HCl/H2O 10%, r.t., 4 h 2. NaOH, H2O/CHCl3; (v) 2-formylbenzoic acid, pTSA, EtOH, MW, 100 ◦C,
30 min; 71%; (vi) 1. 2-methylbenzyl chloride, NaN3, Et3N, H2O/tBuOH, r.t., 1 h, 2. sodium ascorbate,
(−)-6 or (−)-8, CuSO4, r.t. 8 h, 70–72%; (vii) MW, DCB, 220 ◦C, 60 min, 300 W, 70–72%.
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Racemic N-Boc-protected amino acids (±)-3 and (±)-12 were produced from the corresponding
diendo- and diexo-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acids (±)-2 and (±)-11 according to
an earlier procedure [54]. The synthesis of enantiomeric Boc-protected amino acids (−)-3 and (−)-12
started from enantiomeric 2-aminonorbornene esters (−)-1 and (−)-10, as depicted in Schemes 1 and 2.
The starting enantiomeric 2-aminonorbornene esters (−)-1 and (−)-10 were prepared from racemic
amino esters (±)-1 and (±)-4 by diastereomeric salt formation as previously described [45].
The free enantiomeric amino esters (−)-1 (ee > 95%) and (−)-10 (ee > 96%) were hydrolyzed with
water under microwave irradiation to furnish amino acids (−)-2 and (–)-11, which were then reacted
with di-tert-butyl dicarbonate affording N-Boc-protected amino acids (−)-3 and (−)-12. They were then
transformed into propargylamides (−)-4 and (−)-13 in tetrahydrofuran using propargylamine in
the presence of N,N′-diisopropylcarbodiimide (DIC) and hydroxybenzotriazole (HOBt). After acidic
deprotection of amides (−)-4 and (−)-13, free amide bases (+)-5 and (+)-14 were used in the next step
without purification.
The reaction of propargylamides 5 and 14 with 2-formylbenzoic acid is plausibly interpreted as a
domino process, in which the first step is the Schiff base formation [47,50]. The Schiff base undergoes
ring closure to give isoindolo[2,1-a]quinazolinones 6 and 15, respectively.
The reaction was implemented by dissolving (+)-5 and (+)-14 in ethanol using one equivalent of
2-formylbenzoic acid and stirring the solution at 100 ◦C for 30 min under microwave irradiation in the
presence of p-toluenesulfonic acid. The 1H NMR spectra revealed the formation of the isoindolo[2,1-a]
quinazoline (−)-6 and (−)-15 (Schemes 1 and 2).
The full NMR signal assignment was carried out for compounds (−)-6 and (−)-15. The relative
configuration of the new hydrogen in the product from the diexo isomer, according to the characteristic
NOE crosspeaks, is in trans arrangement with the annelated hydrogen atoms in (–)-6. The characteristic
structure crosspeak was found for (−)-6 between protons C(6a)-H and C(13)-H. For the diendo isomer,
in the product of the ring closure reaction, the annelated hydrogen atoms and the relative configuration
of the new hydrogen are trans in (−)-15. For (−)-15 the characteristic structure crosspeaks were found
between the C(6a)-H and C(3)-H protons.
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In the next step the 1,2,3-triazole ring was formed by click reaction using Cu(I)-catalyzed
azide/alkyne (CuAAc) cycloaddition. The azide was synthesized in situ by dissolving sodium azide
in the mixture of 2-methylbenzyl chloride, trimethylamine, and tert-butyl alcohol and stirring at room
temperature for 1 h [35]. Afterwards, (−)-6 or (−)-15 was added along with copper(II) sulfate and
sodium ascorbate as a reducing agent. The nascent copper(I) acting as the catalyst is responsible for
the regioselectivity [35]. The CuAAC reaction of the terminal alkyne moiety of (−)-6 and (−)-15 was
completely regioselective affording 1,4-disubstituted triazoles (−)-7 and (−)-16.
In the last step, RDA reaction was performed with (−)-6, (−)-7 and (−)-15, (−)-16 resulting in
(−)-8, (−)-9 and (+)-8, (+)-9, respectively. The reactions were carried out in 1,2-dichlorobenzene by
stirring under microwave irradiation at 220 ◦C for 60 min.
An alternative pathway for the synthesis of (−)-9 and (+)-9 was also tested. It was implemented
after the RDA reaction of (−)-6 and (−)-15 and, as expected, it provided the product molecules with
the same structures formed in the original pathway (Schemes 1 and 2).
3. Materials and Methods
3.1. General Methods
1H NMR spectra were recorded at 500.20 MHz, while the 13C NMR spectra were measured
at 125.62 MHz in CDCl3 or in DMSO-d6 at ambient temperature, with a Bruker AV NEO Ascend
500 spectrometer (Bruker Biospin, Karlsruhe, Germany) with Double Resonance Broad Band Probe
(BBO). Chemical shifts are given, relative to tetramethysilane (TMS) as internal standard, in δ (ppm).
Elemental analyses were performed with a Perkin–Elmer CHNS-2400 Ser II Elemental Analyzer.
Microwave-promoted reactions were carried out in sealed reaction vials (10 mL) in a microwave (CEM,
Discover, SP) cavity (CEM Corporation, Matthwes, NC, USA). Optical rotations were measured with a
Perkin–Elmer 341 polarimeter (Perkin–Elmer, Shelton, CT, USA). Melting points were determined with
a Hinotex-X4 micro melting point apparatus (Hinotek, Ningbo, China) and are uncorrected. Racemic
diendo- and diexo-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acids (±)-2 and (±)-11 were prepared
according to a literature procedure [55,56].
The enantiomers of 2-aminonorbornene esters (+)-1, (−)-1, (+)-10 and (−)-10 were prepared from
racemic 2-aminonorbornene esters via diastereomeric salt formation with O,O′-di-p-toluoyltartaric
acid (DPTTA) and O,O′-dibenzoyltartaric acid (DBTA) as previously published [45]. The ee values
of (+)-1 and (−)-1 were determined by a literature method [45]. The ee values for (+)-10 (92%) and
(−)-10 (98%) were determined by HPLC using Phenomenex-IA column after derivatization with
benzoyl chloride in the presence of TEA. Analytical conditions were as follows: eluent: a mixture of
n-hexane and isopropyl alcohol (IPA) (70:30), flow rate: 0.3 mL·min−1, detection at 254 nm, retention
times: (−)-10: 40.81 min (antipode: 25.33 min). The ee values for (−)-4 (98%), (+)-4 (95%), (−)-13
(95%) and (+)-13 (96%) were determined by GC on a Chirasil-L-Val column (25 m): 180 ◦C isotherm,
1 mL·min–1, retention times (−)-13: 4.91 min, (+)-13: 4.52 min; flow rate 1 mL·min−1, 160 ◦C for 5 min
→ 180 ◦C (rate of temperature rise 10 ◦C/min; retention times (−)-4: 11.84 (min), (+)-4: 12.64 (min).
The ee values of the domino ring closure compounds (−)-6 and (+)-6 were identified by HPLC using
Chiracel-OD-H column, eluent: a mixture of n-hexane and IPA (70:30), flow rate: 0.15 mL·min−1,
detection at 254 nm, retention times (−)-6: 61.83 min, (+)-6: 66.29 min. The ee values of the domino ring
closure products (−)-15 and (+)-15 were identified by HPLC using Phenomenex-IA column, eluent: a
mixture of n-hexane and IPA (60:40), flow rate: 1 mL·min−1, detection at 254 nm, retention times (−)-15:
22.04 min, (+)-15: 42.99 min. The ee values of the RDA products (−)-8 and (+)-8 were determined by
HPLC using Phenomenex-IA column, eluent: a mixture of n-hexane and IPA (70:30 containing 0.1%
DEA), flow rate: 0.5 mL·min−1, detection at 254 nm, retention times (−)-8: 80.88 min, (+)-8: 76.58 min.
The ee values of RDA products (−)-9 and (+)-9 were determined by HPLC using ChiralPak-IA column,
eluent: a mixture of n-hexane and IPA (60:40 containing 0.1% DEA), flow rate: 0.5 mL·min−1, detection
at 254 nm, retention times (−)-9: 26.76 min, (+)-9: 23.87 min.
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3.2. Synthesis of New Compounds
3.2.1. Synthesis of Amino Acids [(+)-2, (−)-2, (+)-11, (−)-11]
2-Aminonorbornene ester hydrochlorides (+)-1, (−)-1 [45] or (+)-10, (−)-10 [45] (3.00 g, 13.82 mmol
in 30 mL H2O) were treated with 10% aqueous NaOH solution (30 mL) to liberate the free acids. The
aqueous layer was extracted with CHCl3 (3× 30 mL). The combined organic phase was dried (Na2SO4)
and the solvent was evaporated. The residue was diluted in water (2 mL) in a 10-mL pressurized
reaction vial, and the solution was stirred and warmed to 100 ◦C for 30 min at max. 300 W microwave
irradiation. The solvent was evaporated, and the crude product was filtered off from acetone and
recrystallized from water/acetone. [(−)-2]: white crystals (90% yield), m.p. 258–262 ◦C. Lit m.p.
>260 ◦C, [α]20D = −12.1 (c = 0.5, H2O), lit [57] = [α]20D = −12.3 [57] (c = 0.3, H2O). [(+)-2]: white crystals
(91% yield), m.p. 257–260 ◦C [α]20D = +12.0 (c = 0.5, H2O). Lit. [58] [α]
20
D = +13.8 (c = 1, H2O). [(−)-11]:
white crystals (85% yield) m.p. 236–238 ◦C, [α]20D = −62 (c = 0.5, H2O). [(+)-11]: white crystals
(91% yield) m.p. 233–237 ◦C, [α]20D = +62 (c = 1, H2O). 1H and 13C NMR data of the enantiomeric amino
acids were identical with those of the racemic compounds [55,56].
3.2.2. Synthesis of Boc-Protected Amino Acids [(+)-3, (−)-3, (+)-12, (−)-12]
To a solution of the appropriate 2-aminonorbornene carboxylic acid [(+)-2, (−)-2 (+)-11 or (−)-11,
3.1 g, 10 mmol] in 100 mL of a 2:1 dioxane/H2O mixture, 25 mL 1 M NaOH was added. The solution
was cooled to 0 ◦C and Boc2O (2.4 g, 11 mmol) was added. The mixture was stirred at 0 ◦C for 1 h,
warmed to r.t., stirred for 4 h and, finally, it was evaporated to 30 mL. The solvent was acidified with
10% H2SO4 (pH = 2.5) and the resulting mixture was extracted with EtOAc (3 × 50 mL). The solvent
was evaporated, and the crude product was filtered off from Et2O and recrystallized from iPr2O.
[(−)-3]: white crystals (87% yield), m.p. 133–135 ◦C, [α]20D = −78 (c = 1, EtOH). [(+)-3]: white crystals
(91% yield), m.p. 136–137 ◦C, [α]20D = +76 (c = 1, EtOH). [(−)-12]: white crystals (85% yield), m.p.
132–135 ◦C, [α]20D = −14 (c = 1, EtOH). [(+)-12]: white crystals (91% yield), m.p. 133–134 ◦C, [α]20D = +13
(c = 1, EtOH). 1H and 13C NMR data of the enantiomeric amino acids were identical with those of the
racemic compounds [54–59].
3.2.3. Synthesis of Boc-Protected Propargyl Amides [(+)-4, (−)-4, (+)-13, (−)-13]
A mixture of the appropriate amino acid [(+)-3, (−)-3 (+)-12 or (−)-12, 2.53 g, 10 mmol],
hydroxybenzotriazole (1.83 g, 12 mmol), N,N′-diisopropylcarbodiimide (DIC) (1.51 g, 12 mmol), and
propargylamine (0.55 g, 0.7 mL, 10 mmol) was stirred in THF (50 mL) overnight at r.t. After completion
of the reaction (checked by thin layer chromatography), the solvent was evaporated. Purification of
the residue by column chromatography over silica gel with EtOAc gave the desired products.
tert-Butyl ((1R,2R,3S,4S)-3-(prop-2-yn-1-ylcarbamoyl)bicyclo[2.2.1]hept-5-en-2-yl)carbamate [(−)-4]: White
crystals (75% yield), m.p. 128–130 ◦C, [α]20D = −38 (c = 1, EtOH), 1H-NMR (500 MHz, CDCl3, 30 ◦C):
δ = 1.42 (s, 9H, CH3) 1.60 (m, 1H, H-7), 2.10 (m, 1H, H-7), 2.20 (t, J = 2.3 Hz, 1H, C≡CH) 2.35 (d,
J = 8.2 Hz, 1H, H-2), 2.69 (m, 1H, H-1), 2.98 (m, 1H, H-4), 3.85–3.92 (m, H, H-4), 4.11–4.16 (m, 1H,
NCH2), 5.09–5.21 (m, 1H, NCH2) 5,91 (s, 1H, NH) 6.14–6.23 (m, 2H, H-5, H-6) 13C NMR (125 MHz,
CDCl3, 30 ◦C): δ = 28.4, 29.4, 44.9, 45.6, 48.0, 48.1, 53.0, 71.7, 79.3, 79.5, 137.5, 138.8, 155.9, 172.8 ppm.
C16H22N2O3 (290.36): calcd. C, 66.18; H, 7.64; N, 9.65; found C 66.44; H 7.91; N 9.42.
tert-Butyl ((1S,2S,3R,4R)-3-(prop-2-yn-1-ylcarbamoyl)bicyclo[2.2.1]hept-5-en-2-yl)carbamate [(+)-4]: White
crystals (74% yield). m.p. 129–131 ◦C, [α]20D = +37 (c = 1, EtOH).
tert-Butyl ((1R,2S,3R,4S)-3-(prop-2-yn-1-ylcarbamoyl)bicyclo[2.2.1]hept-5-en-2-yl)carbamate [(−)-13]: White
crystals (72% yield), m.p. 161–163 ◦C, [α]20D = −3.7 (c = 0.5, EtOH), 1H-NMR (500 MHz, CDCl3, 30 ◦C):
δ = 1.29–1.50 (m, 11H, CH3, H-7, H-7) 2.19 (t, J = 2.3 Hz, 1H, C≡CH) 2.98–3.10 (m, 3H, H-1, H-2, H-4),
3.75–3.83 (m, H, H-3), 4.03–4.13 (m, 1H, NCH2), 4.78–4.86 (m, 1H, NCH2) 6.06–6.11 (m, 1H, H-6) 6.20
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(s, 1H, NH) 6.59–6.61 (m, 1H, H-5), 13C NMR (125 MHz, CDCl3, 30 ◦C): δ = 28.4, 29.4, 46.3, 47.1, 47.7,
53.0, 71.7, 79.3, 79.5, 137.5, 138.8, 155.9, 172.8 ppm. C16H22N2O3 (290.36): calcd. C, 66.18; H, 7.64; N,
9.65; found C 66.41; H 7.71; N 9.52.
tert-Butyl ((1S,2R,3S,4R)-3-(prop-2-yn-1-ylcarbamoyl)bicycle[2.2.1]hept-5-en-2-yl)carbamate [(+)-13]: White
crystals (74% yield), m.p. 160–163 ◦C, [α]20D = +4.1 (c = 0.5, EtOH).
3.2.4. Synthesis of Domino Ring Closure Products [(−)-6, (+)-6, (−)-15 and (+)-15]
The mixture of Boc-protected amides (+)-4, (−)-4 or (+)-13, (−)-13 (2.32 g, 8 mmol in 15 mL H2O)
was stirred with 10% aqueous HCl solution (10 mL) at r.t. for 6 h. The aqueous layer was neutralized
with 10% aqueous NaOH solution and extracted with CH2Cl2 (3 × 30 mL). The combined organic
phase was dried (Na2SO4) and the solvent was evaporated. The resulting amides were used for the
next steps without purification. Amide (+)-5, (−)-5, (+)-14 or (−)-14 (1.33 g, 7 mmol), 2-formylbenzoic
acid (1.05 g, 7 mmol), and pTSA (20 mol%) were dissolved in EtOH (5 mL) in a 10-mL pressurized
reaction vial, and the solution was warmed to 100 ◦C for 30 min at max. 300 W microwave irradiation.
Upon completion of the reaction (monitored by TLC) the solvent was evaporated and the crude solid
was filtered off from Et2O and recrystallized from EtOH.
(1S,4R,4aR,6aS,12aS)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(−)-6]: White crystals (71% yield), m.p. 189–191 ◦C, [α]20D = −19 (c = 0.5, EtOH), 1H-NMR
(500 MHz, CDCl3, 30 ◦C): δ = 1.66–1.80 (m, 2H, H-13, H-13) 2.45 (t, J = 2.4 Hz, 1H, C≡CH), 2.63–2.69
(m, 1H, H-4a) 2.91–2.96 (m, 1H, H-4), 3.46–3.48 (m, 1H, H-1), 3.80–3.83 (m, 1H, H-12a), 4.53–4.59
(m, 1H, NCH2), 5.40–5.52 (m, 1H, NCH2) 6.18 (s, 1H, H-6a) 6.35–6.44 (m, 2H, H-2, H-3) 7.59–8.10
(m, 4H, Ar), 13C NMR (125 MHz, CDCl3, 30 ◦C): δ = 32.5, 42.4, 45.7, 49.2, 50.1, 50.4, 68.1, 74.5, 77.8,
125.1, 125.3, 130.8, 132.5, 138.5, 138.8, 139.5, 167.2, 171.3. ppm. C19H16N2O2 (304.34.36): calcd. C, 74.98;
H, 5.30; N, 9.20; found C 74.91; H 5.42; N 9.35.
(1R,4S,4aS,6aR,12aR)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(+)-6]: White crystals (69% yield), m.p. 189–192 ◦C, [α]20D = +18 (c = 0.5, EtOH).
(1S,4R,4aS,6aR,12aR)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(−)-15]: White crystals (70% yield), m.p. 189–191 ◦C, [α]20D =−34.9 (c = 0.5, EtOH), 1H-NMR
(500 MHz, CDCl3, 30 ◦C): δ = 1.61–1.62 (m, 2H, H-13, H-13) 2.40 (t, J = 2.1 Hz, 1H, C≡CH), 3.10–3.19
(m, 1H, H-4a) 3.25–3.35 (m, 1H, H-4), 3.47–3.54 (m, 1H, H-1), 3.60–3.73 (m, 1H, H-12a), 5.22–5.39
(m, 2H, NCH2), 5.97 (s, 1H, H-6a), 6.26–6.31 (m, 1H, H-3), 6.44–6.52 (m, 1H, H-2) 7.52–7.96 (m, 4H, Ar),
13C NMR (125 MHz, CDCl3, 30 ◦C): δ = 32.2, 32.5, 42.4, 45.3, 49.2, 50.1, 50.4, 68.1, 74.5, 78.2, 125.1, 155.3,
130.8, 132.5, 138.5, 138.8, 139.5, 167.2, 171.3. ppm. C19H16N2O2 (304.34.36): calcd. C, 74.98; H, 5.30; N,
9.20; found C 74.82; H 5.51; N 9.32.
(1R,4S,4aR,6aS,12aS)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(+)-15]: White crystals (74% yield), m.p. 189–192 ◦C, [α]20D = +36 (c = 0.5, EtOH).
3.2.5. General Procedure for the Synthesis of (−)-7, (+)-7, (−)-16 and (+)-16 by Click Reaction
A solution of 2-methylbenzyl chloride (1.1 mmol), NaN3 (1 mmol), and Et3N (1.3 mmol) in
H2O/tBuOH (1:1, 10 mL) was stirred at r.t. for 1 h. Subsequently, a mixture of 1,4-methanoisoindolo
[2,1-a]quinazoline-5,11-dione derivative ((−)-6, (+)-6, (−)-15 or (+)-15; 1 mmol), sodium ascorbate
(0.15 mmol), and CuSO4 (10 mol%) was added to the freshly prepared azide derivative and the mixture
was stirred at r.t. for 8 h. The mixture was diluted with H2O and extracted with EtOAc. The organic
phase was dried (Na2SO4), the solvent was evaporated off. Purification of the residue by column
chromatography over silica gel with EtOAc gave the desired products. (The same procedure was used
for the synthesis of (−)-9 and (+)-9 by click reaction starting from (−)-8 and (+)-8).
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(1S,4R,4aR,6aS,12aS)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-1,4-
methanoisoindolo[2,1-a]quinazoline-5,11-dione [(−)-7]: White crystals (70% yield), m.p. 100–107 ◦C,
[α]20D = −20 (c = 0.5, EtOH), 1H-NMR (500 MHz, CDCl3, 30 ◦C): δ = 1.31–1.42 (m, 2H, H-13) 2.26 (s, 3H,
CH3), 2.54–2.58 (m, 1H, H-4a) 2.81–2.85 (m, 1H, H-4), 3.17–3.21 (m, 1H, H-1), 4.50–4.54 (m, 1H, H-12a),
4.57–4.64 (d, J = 15.9 Hz, 1H, NCH2), 5.35–5.42 (d, J = 15.9 Hz, 1H, NCH2), 5.53 (s, 2H, NCH2Ar) 6.10 (s,
1H, H-6a), 6.26–6.41 (m, 2H, H-2, H-3), 7.03–7.33 (m, 4H, Ar), 7.37 (s, 1H, CHtriazol) 7.52–8.34 (m, 4H,
Ar), 13C NMR (125 MHz, CDCl3, 30 ◦C): δ = 19.0, 37.5, 41.9, 44.5, 48.6, 49.4, 49.6, 52.4, 68.1, 122.6, 124.4,
126.5, 126.7, 129.2, 129.3, 130.3, 131.0, 131.9, 132.1, 132.4, 136.7, 138.2, 139.6, 144.0, 166.9, 171.5. ppm.
C27H25N5O2 (451.52): calcd. C, 71.82; H, 5.58; N, 15.51; found C 71.93; H 5.47; N 15.35.
(1R,4S,4aS,6aR,12aR)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-1,4-
methanoisoindolo[2,1-a]quinazoline-5,11-dione [(+)-7]: White crystals (74% yield), m.p. 100–102 ◦C, [α]20D =
+20 (c = 0.5, EtOH).
(1S,4R,4aS,6aR,12aR)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-1,4-
methanoisoindolo[2,1-a]quinazoline-5,11-dione [(−)-16]: White crystals (72% yield), m.p. 128–130 ◦C,
[α]20D = −20 (c = 0.5, EtOH), 1H-NMR (500 MHz, CDCl3, 30 ◦C): δ = 1.53–1.65 (m, 2H, H-13) 2.28 (s,
3H, CH3), 3.08 (m, 1H, H-4a) 3.20–3.25 (m, 1H, H-4), 3.28–3.33 (m, 1H, H-1), 4.45–4.55 (m, 1H, H-12a),
5.20–5.29 (m, 2H, NCH2), 5.47 (m, 2H, NCH2Ar) 5.64 (m, 1H, H-3), 5.79 (s, 1H, H-6a), 5.98 (m, 1H, H-2)
7.03–7.32 (m, 4H, Ar), 7.40 (s, 1H, CHtriazol) 7.51–8.40 (m, 4H, Ar), 13C NMR (125 MHz, CDCl3, 30 ◦C):
δ = 19.0, 37.2, 42.7, 47.8, 48.8, 48.9, 50.0, 52.4, 68.6, 122.9, 124.2, 126.8, 126.8, 129.3, 129.4, 130.0, 131.1,
131.9, 131.9, 132.4, 135.4, 136.7, 137.0, 139.7, 144.0, 167.5, 171.2 ppm. C27H25N5O2 (451.52): calcd. C,
71.82; H, 5.58; N, 15.51; found C 71.91; H 5.43; N 15.32.
(1R,4S,4aR,6aS,12aS)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-1,4-
methanoisoindolo[2,1-a]quinazoline-5,11-dione [(+)-16]: White crystals (74% yield), m.p. 97–99 ◦C, [α]20D =
+19.3 (c = 0.5, EtOH).
3.2.6. RDA Protocols for the Synthesis of Pyrimido[2,1-a]isoindols [(−)-8 (+)-8, (−)-9, (+)-9]
Isoindoloquinazoline derivatives [(−)-6, (+)-6, (−)-7, (+)-7, (−)-15, (+)-15, (−)-16, (+)-16, 0.5 mmol]
were dissolved in 5 mL 1,2-dichlorobenzene. The solution was stirred and heated to 220 ◦C for 60 min
at max. 300 W microwave irradiation. Then the solvent was evaporated, the residue was dissolved in
EtOAc and purified by column chromatography on silica gel eluting with EtOAc.
(S)-1-(Prop-2-yn-1-yl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione [(−)-8]: White crystals (52% yield),
m.p. 91–93 ◦C, [α]20D = −376 (c = 0.2, EtOH), 1H-NMR (500 MHz, CDCl3, 30 ◦C): δ = 2.45 (t, J = 2.5 Hz,
1H, C≡CH), 3.73 (dd, J = 17.7, 2.1, 1H,CH2) 5.15 (d, J = 17.7 Hz, 1H, CH2) 5.54 (d, J = 7.6 Hz, 1H, H-3)
6.20 (s, 1H, H-10b) 7.66–8.10 (m, 5H, Ar, H-4), 13C NMR (125 MHz, CDCl3, 30 ◦C): δ = 31.3, 69.8, 73.7,
79.9, 106.8, 125.4, 125.4, 130.8, 131.7, 133.7, 133.7, 138.5, 164.3, 165.4. ppm. C14H10N2O2 (238.24): calcd.
C, 70.58; H, 4.23; N, 11.76; found C 70.81; H 4.41; N 11.52.
(R)-1-(Prop-2-yn-1-yl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione [(+)-8]: White crystals (51% yield),
m.p. 93–95 ◦C, [α]20D = +368 (c = 0.2, EtOH).
(S)-1-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione
[(−)-9]: White crystals (72% yield), m.p. 199–200 ◦C, [α]20D = −295 (c = 0.2, EtOH), 1H-NMR (500 MHz,
CDCl3, 30 ◦C): δ = 2.31 (s, 3H, CH3), 4.45 (d, J = 15.7 Hz, 1H, NCH2CH) 5.15 (d, J = 15.8 Hz, 1H,
NCH2CH) 5.43–5.64 (m, 3H, NCH2Ar, H-3) 6.18 (s, 1H, H-10b) 7.17–7.31 (m, 4H, Ar) 7.55 (1H, s,
CHtriazol) 7.63–7.95 (m, 4H, Ar) 8.70 (d, J = 7.9 Hz 1H, H-4), 13C NMR (125 MHz, CDCl3, 30 ◦C):
δ = 19.1, 37.2, 52.4, 70.3, 106.9, 123.5, 125.0, 126.7, 127.5, 129.2, 129.6, 130.6, 131.1, 131.6, 132.3, 133.6,
133.6, 136.9, 138.9, 143.8, 164.4, 165.8. ppm. C22H19N5O2 (385.42): calcd. C, 68.56; H, 4.97; N, 18.17;
found C 68.71; H 4.81; N 18.39.
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(R)-1-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione
[(+)-9]: White crystals (72% yield), m.p. 199–200 ◦C, [α]20D = +287 (c = 0.2, EtOH).
3.2.7. Representative Data for the Racemates (±)-4–(±)-16
tert-Butyl ((1R*,2R*,3S*,4S*)-3-(prop-2-yn-1-ylcarbamoyl)bicyclo[2.2.1]hept-5-en-2-yl)carbamate [(±)-4]:
Yield 75%, white crystals, m.p. 133–135 ◦C.
(1S*,4R*,4aR*,6aS*,12aS*)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(±)-6]: Yield 68%, white crystals, m.p. 235–240 ◦C.
(1S*,4R*,4aR*,6aS*,12aS*)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-
1,4-methanoisoindolo[2,1-a]quinazoline-5,11-dione [(±)-7]: Yield 79%, pale-yellow crystals, m.p. 163–165 ◦C.
1-(Prop-2-yn-1-yl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione [(±)-8]: Yield 68%, white crystals, m.p.
166–168 ◦C.
1-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione [(±)-9]:
Yield 61%, white crystals, m.p. 192–195 ◦C.
tert-Butyl ((1R*,2S*,3R*,4S*)-3-(prop-2-yn-1-ylcarbamoyl)bicyclo[2.2.1]hept-5-en-2-yl)carbamate [(±)-13]:
Yield 71%, white crystals, m.p. 160–161 ◦C.
(1S*,4R*,4aS*,6aR*,12aR*)-6-(Prop-2-yn-1-yl)-1,4,4a,6,6a,12a-hexahydro-1,4-methanoisoindolo[2,1-a]quinazoline-
5,11-dione [(±)-15]: Yield 71%, white crystals, m.p. 215–220 ◦C.
(1S*,4R*,4aS*,6aR*,12aR*)-6-((1-(2-Methylbenzyl)-1H-1,2,3-triazol-4-yl)-methyl)-1,4,4a,6,6a,12a-hexahydro-
1,4-methanoisoindolo[2,1-a]quinazoline-5,11-dione [(±)-16]: Yield 75%, white crystals, m.p. 163–165 ◦C.
Supplementary materials contain obtained 1H and 13C NMR spectra of compounds 4–16, HPLC
chromatograms of domino products (+)-6, (−)-6, (+)-15 and (−)-15 and RDA products (+)-8, (−)-8,
(+)-9 and (−)-9 presented in the manuscript.
4. Conclusions
In summary, we have developed an efficient procedure for the synthesis of novel racemic
and enantiomeric 1,2,3-triazole pharmacophore-based pyrimido[2,1-a]isoindoles in the reaction of
N-propargyl-substituted norbornenecarboxamides through a traceless chirality transfer strategy.
It involves a three-step reaction using a domino and a copper-catalyzed click reaction as well as
an RDA reaction step. The stereochemical information to the newly formed stereogenic centers of the
isoindoloquinazolinones was facilitated by the high rigidity of the norbornene skeleton. The absolute
configuration of the final products was characterized, because the configuration did not change during
subsequent steps. The main advantages of this protocol are simplicity, high yield, short time, mild
reaction conditions and easy work-up.
Supplementary Materials: The following are available online. The 1H and 13C NMR spectra of compounds 4–16
and HPLC chromatograms of domino products (+)-6, (−)-6, (+)-15 and (−)-15 and RDA products (+)-8, (−)-8,
(+)-9 and (−)-9 are available as supporting data.
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